Received: 8 February 2019
Accepted: 1 October 2019
First Online: 5 November 2019
Ethics approval and consent to participate
: The cohort 1 was collected from the data of the large project on “Severe Sepsis and inflammation monitoring” approved by Cochin Hospital Ethics Committee (# CCPPRB 2061), Assistance Publique-Hôpitaux de Paris. For each patient of the cohort 1, a clear explanation of the justification to use IFNγ was given, based on the literature and on the experience of the research clinical team. According to the French law and with the agreement of the Institutional Pharmacy Board, IFNγ was proposed as a compassionate treatment with clear explanation given to the patient’s next of kin about the potential risks and benefits.For each pediatric case, IFNγ administration was a multidisciplinary decision between intensivists, surgeons and hepatologists, which was proposed to the parents as a compassionate treatment. The compassionate therapy by IFNγ was validated by institutional pharmacist after a review of the literature. Decisional process was notified in the hospitalization records and synthesis note with signature on the medical charts.
: Written informed consent was obtained from the parent of the patients for publication of these Case Report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
: None of the authors have any competing interests regarding this study. In this study, the support for the immunological assessments was covered by payment of additional immune tests in the global cost for care.